奥浦迈回复问询函：收购澎立生物将直接提升财务数据

Core Viewpoint - The company, Shanghai Aopumai Biotechnology Co., Ltd., is undergoing a restructuring plan involving the acquisition of 100% equity in Pengli Biotechnology for 1.451 billion yuan, aiming to enhance its service offerings and financial performance [2][3]. Financial Impact - The acquisition is projected to increase the company's net profit attributable to shareholders by over 40 million yuan, with significant improvements in key financial metrics post-transaction [2][3]. - Pre-transaction financials for 2024 show total assets of 2.286 billion yuan, total liabilities of 191 million yuan, and a net profit of 21.052 million yuan, while post-transaction projections indicate total assets of 4.025 billion yuan, total liabilities of 1.183 billion yuan, and a net profit of 62.8 million yuan, reflecting increases of 76.07%, 519.24%, and 111.25% respectively [3]. Business Strategy - The merger aims to create a comprehensive service chain from early drug development to commercial production, transitioning the company from a single product supplier to a comprehensive solution provider [2][3]. - The company plans to enhance its resilience against market fluctuations, diversify customer risk, and reduce dependency on single products through this acquisition [4]. Performance Challenges - The company has faced declining net profits, with a 48.72% drop in 2023 and a further 61.04% decline in 2024, despite a 22.26% increase in revenue [6][7]. - Factors contributing to the profit decline include increased fixed costs from new projects, loss of high-tech enterprise status leading to higher tax burdens, and asset impairment losses totaling 16.95 million yuan [7][8]. Market Position - The company's stock has underperformed since its IPO, with a current share price of 38.49 yuan, down from the initial offering price of 80.20 yuan, resulting in a market capitalization of 4.37 billion yuan [10].